Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PRIORITY

Financiado

Cerrado

Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevent...

Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy In TYpe 2 diabetic patients with normoalbuminuria Patients with diabetes are at risk of developing diabetic nephropathy, which will ultimately result in the requirement for renal replacement therapy and is also associated with high cardiovascular morbidity and mortality. Detectio... ver más

31/12/2018

REGIONH

9M€

Presupuesto del proyecto: 9M€

Líder del proyecto

REGION HOVEDSTADEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 18 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2018-12-31 No tenemos la información de la convocatoria

0% 69% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

18 Participantes

REGIONH

0.00€ | Lider

HCTC

N.D. | Participante

MOSAIQUES DIAGNOSTICS GMBH

N.D. | Participante

Ss. CYRIL AND METHODIUS UNIV...

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

ELECTRIC Efficacy of Leveraging Endocrine Therapies for Renoprotectio... 277K€ Cerrado

SAF2017-89782-R COMO MODELAR LA NEFROPATIA DIABETICA: RESTABLECIENDO EL EPIG... 182K€ Cerrado

BEAt-DKD Biomarker Enterprise to Attack DKD Sofia ref. 115974 31M€ Cerrado

DNCURE Dynamic signalling networks in Diabetic Nephropathy DN N... 2M€ Cerrado

DIADRUG Insulin resistance and diabetic nephropathy development of... 2M€ Cerrado

TargetCKD Identification of novel diagnostic, predictive and therapeut... 2M€ Cerrado

Líder del proyecto

REGION HOVEDSTADEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 9M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Patients with diabetes are at risk of developing diabetic nephropathy, which will ultimately result in the requirement for renal replacement therapy and is also associated with high cardiovascular morbidity and mortality. Detection of low concentrations of albuminuria in urine (microalbuminuria) is the current clinical standard for detecting those at significant risk and targeting preventive treatment. However, albuminuria is of low specificity at early stages of disease, and of considerable biological variability, hence a poor predictor at early stages of disease. In two independent studies we have demonstrated that urinary proteomics offers the prospect of detecting nephropathy earlier in the preclinical phase, enabling targeted treatment at an earlier stage. We propose to assess the potential of this technology to identify normoalbuminuric patients at risk and to target therapy with an aldosterone receptor antagonist (spironolactone) as add-on to recommended therapy including angiotensin converting enzyme (ACE) inhibition or angiotensin II receptor blockers (ARBs) according to national guidelines. We will test the following hypotheses: (1) urinary proteomics predicts progression of albuminuria (as a surrogate marker for the development of overt nephropathy) in a cohort of 3280 type 2 diabetic patients with normal urinary albumin excretion, and (2) early initiation of intensive preventive therapy directed by urinary proteomics reduces progression of albuminuria in those 20 % at high risk and thereby delay progression to overt nephropathy and spare treatment for those with low risk, paving the way of personalised medicine. This will be the first biomarker-directed therapy trial for primary prevention of diabetic kidney disease. Additional clinical and circulating biomarkers will be assessed and models to predict progression of albuminuria including clinical factors, biomarkers and proteomics will be developed.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores